These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 10478177)

  • 1. [Present and future in brachytherapy--from the discovery of radium to the 21st century].
    Inoue T; Inoue T
    Gan To Kagaku Ryoho; 1999 Aug; 26(9):1254-60. PubMed ID: 10478177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical evaluation based on cost-effectiveness].
    Inoue T; Inoue T
    Gan To Kagaku Ryoho; 1998 Jan; 25(1):13-9. PubMed ID: 9464324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of HDR (192Ir) versus MDR (137Cs) intracavitary brachytherapy for carcinoma of the uterine cervix.
    Tanaka E; Oh RJ; Yamada Y; Shiomi H; Nakamura S; Shimamoto S; Teshima T; Inoue T; Inoue T
    Brachytherapy; 2003; 2(2):85-90. PubMed ID: 15062145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
    Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
    Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer.
    Kucera H; Pötter R; Knocke TH; Baldass M; Kucera E
    Wien Klin Wochenschr; 2001 Jan; 113(1-2):58-62. PubMed ID: 11233470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma.
    Lertsanguansinchai P; Lertbutsayanukul C; Shotelersuk K; Khorprasert C; Rojpornpradit P; Chottetanaprasith T; Srisuthep A; Suriyapee S; Jumpangern C; Tresukosol D; Charoonsantikul C
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1424-31. PubMed ID: 15275728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series.
    Ferrigno R; Nishimoto IN; Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1108-16. PubMed ID: 15990016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
    Nickers P; Thissen B; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
    King CR
    Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
    Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of brachytherapy and surgery for the treatment of stage I-II squamous cell carcinoma of the tongue.
    Umeda M; Komatsubara H; Ojima Y; Minamikawa T; Shibuya Y; Yokoo S; Ishii J; Komori T
    Int J Oral Maxillofac Surg; 2005 Oct; 34(7):739-44. PubMed ID: 15921890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer.
    Hepel JT; Syed AM; Puthawala A; Sharma A; Frankel P
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1444-50. PubMed ID: 16029806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Brachytherapy for prostate cancer: high dose rate or low-dose rate?].
    Cosset JM; Haie-Meder C
    Cancer Radiother; 2005 Dec; 9(8):610-9. PubMed ID: 16226473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose rate interstitial brachytherapy for mobile tongue cancer: Part 2. Phase III trial of HDR versus LDR interstitial brachytherapy for T1-T2N0 carcinoma of the mobile tongue.
    Inoue T; Inoue T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():291-5. PubMed ID: 10895169
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose rate interstitial brachytherapy for stage I-II tongue cancer.
    Umeda M; Komatsubara H; Nishimatsu N; Yokoo S; Shibuya Y; Komori T
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Nov; 90(5):667-70. PubMed ID: 11077395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.